Equities

PureTech Health PLC

PRTC:LSE

PureTech Health PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)126.60
  • Today's Change-1.60 / -1.25%
  • Shares traded687.28k
  • 1 Year change-13.99%
  • Beta1.4686
Data delayed at least 20 minutes, as of Feb 06 2026 16:56 GMT.
More ▼

Profile data is unavailable for this security.

About the company

PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

  • Revenue in GBP (TTM)4.70m
  • Net income in GBP37.24m
  • Incorporated2015
  • Employees56.00
  • Location
    PureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
  • Phone+1 (617) 482-2333Fax+1 (617) 482-3337
  • Websitehttps://puretechhealth.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Hemogenyx Pharmaceuticals PLC0.00-7.81m66.45m16.0066.45m16.00
4Basebio PLC1.78m-14.41m87.02m--87.02m--
Bioventix PLC13.12m7.58m88.82m16.0088.82m16.00
Scancell Holdings Plc4.71m-5.51m134.91m60.00134.91m60.00
Faron Pharmaceuticals Oy0.00-26.87m193.41m25.00193.41m25.00
Avacta Group Plc-11.09m-33.09m266.45m151.00266.45m151.00
Puretech Health PLC4.70m37.24m304.08m56.00304.08m56.00
Oxford BioMedica plc151.21m-37.07m977.70m900.00977.70m900.00
Data as of Feb 06 2026. Currency figures normalised to PureTech Health PLC's reporting currency: UK Pound GBX

Institutional shareholders

57.85%Per cent of shares held by top holders
HolderShares% Held
Invesco Asset Management Ltd.as of 01 Aug 202541.01m16.97%
Citigroup Global Markets, Inc. (Investment Management)as of 17 Nov 202514.57m6.03%
Lansdowne Partners (UK) LLPas of 31 Mar 202514.44m5.97%
Jupiter Asset Management Ltd.as of 15 Jul 202014.25m5.90%
Baillie Gifford & Co.as of 08 Dec 202511.63m4.81%
Miller Value Partners LLCas of 31 Mar 202110.04m4.15%
Patient Capital Management, Inc.as of 31 Mar 20239.81m4.06%
Tang Capital Management LLCas of 26 Sep 20259.73m4.02%
Eurizon Capital SGR SpAas of 01 Dec 20259.56m3.95%
FIL Investment Advisors (UK) Ltd.as of 31 Mar 20254.79m1.98%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.